Showing 1211-1220 of 1635 results for "".
- Bio-Tissue Expands National Footprint, Ramps Up Sales Force by More than 25 Percenthttps://modernod.com/news/bio-tissue-expands-national-footprint-ramps-up-sales-force-by-more-than-25-percent-2/2476882/Bio-Tissue, a TissueTech company, announced the expansion of its sales force to more effectively meet the needs of clinicians and their patients. “A growing body of scientific evidence has cemented CAM as a mainstay treatment for ocular surface diseases,” Grady Grant III, TissueTech Vice P
- Bio-Tissue Expands National Footprint, Ramps Up Sales Force by More than 25 Percenthttps://modernod.com/news/bio-tissue-expands-national-footprint-ramps-up-sales-force-by-more-than-25-percent/2479535/Bio-Tissue, a subsidiary of TissueTech, announced the expansion of its sales force to more effectively meet the needs of clinicians and their patients. “A growing body of scientific evidence has cemented CAM as a mainstay treatment for ocular surface diseases,” Grady Grant III, TissueTech
- Eyepromise Introduces Screen Shield Pro All-Natural Eye Vitamin for Screen Time Protection for Adultshttps://modernod.com/news/eyepromise-introduces-screen-shield-pro-all-natural-eye-vitamin-for-screen-time-protection-for-adults/2476661/EyePromise announced the introduction of Screen Shield Pro to its premium eye vitamin line. EyePromise’s Screen Shield Pro is designed to protect and relieve the associated symptoms of digital eye strain of adults (ages 18 and up) who spend 8+ hours staring at digital screens while working, gami
- EyePoint Pharmaceuticals Names New Members of Executive Leadership Teamhttps://modernod.com/news/eyepoint-pharmaceuticals-names-new-members-of-executive-leadership-team/2476642/EyePoint Pharmaceuticals announced the appointment of Scott Jones as Chief Commercial Officer and Said Saim, PhD, as Chief Technology Officer. Mr. Jones will be responsible for the commercialization of Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammatio
- Re-Vana Therapeutics Names International Experts to Inaugural Scientific Advisory Boardhttps://modernod.com/news/re-vana-therapeutics-names-international-experts-to-inaugural-scientific-advisory-board/2476628/Re-Vana Therapeutics announced the formation of its new Scientific Advisory Board (SAB). The newly appointed SAB will strategically advise and support Re-Vana as it develops innovative therapies for a broad range of ophthalmic indications, including wet age-related macular degeneration (AMD), dia
- Nick Mamalis, MD, Named 2019 ASCRS President as ASCRS Unveils New Brandinghttps://modernod.com/news/nick-mamalis-md-named-2019-ascrs-president-as-ascrs-unveils-new-branding/2476560/Nick Mamalis, MD, a well-known ophthalmologist and longtime co-editor of the Journal of Cataract & Refractive Surgery, assumed his role as president of the American Society of Cataract and Refractive Surgery (ASCRS) during the ASCRS meeting’s opening general session here this p
- First Clinical Program Initiated Using Nanoparticles to Treat Retinitis Pigmentosahttps://modernod.com/news/first-clinical-program-initiated-using-nanoparticles-to-treat-retinitis-pigmentosa/2476490/2Ctech announced the initiation of the first-known clinical program to demonstrate the effectiveness and safety of Quantum Dots (QDs) to achieve photovoltaic stimulation of the neural retina for preservation or enhancement of vision in patients with retinal degenerative diseases and, in particula
- Ophthotech Changes Name to Iveric bio as it Transitions to Gene Therapy Companyhttps://modernod.com/news/ophthotech-changes-name-to-iveric-bio-as-it-transitions-to-gene-therapy-company/2476473/Ophthotech announced that as part of its transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited retinal diseases (IRDs) with unmet medical needs, the company
- Alkahest Presents Positive Phase 2a Study Results of AKST4290 for Treatment-Naïve Wet AMDhttps://modernod.com/news/alkahest-presents-positive-phase-2a-study-results-of-akst4290-for-treatment-naive-wet-amd/2476414/Alkahest shared results from its open label study, ALK4290-201. The data were delivered during a podium presentation as the Abstract Winner of the First-time Presentations of Clinical Trials and Late Breakers session at the 2019 Retina World Congress. The study evaluated the therapeutic effect an
- Eyepromise Introduces Screen Shield Teen All-Natural Eye Vitamin for Screen Time Protectionhttps://modernod.com/news/eyepromise-introduces-screen-shield-teen-all-natural-eye-vitamin-for-screen-time-protection/2476410/EyePromise announced the introduction of Screen Shield Teen to its premium EyePromise eye vitamin line. Screen Shield Teen is an ocular nutrition supplement specially formulated to preserve and support visual comfort and wellness for children ages 4-17. The vast majority of teens in the Un